Novel triplet combinations are leading the key developments made in the treatment of patients with relapsed/refractory multiple myeloma in recent years, according to Kelly Godby, MD, who added that despite the impressive responses elicited with these approaches, longer follow-up is needed to determine the overall survival benefit of these approaches.

Kelly Godby, MD, discusses novel triplet combinations and how they are leading the key developments made in the treatment of patients with relapsed/refractory multiple myeloma in recent years.

Click here to read the interview